GlassScriptPhysician profile
Marc C Alembik
NPI 1003899840
$1,669.60
in general payments reported to CMS, 2019-2025
14 companies · $34.61 in 2025
The $34.61 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $42.81 · 2022: $314 · 2023: $70.84 · 2024: $215 · 2025: $34.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $919.21 | 2019-2023 | Da Vinci Surgical System |
| Coopersurgical, INC. | $177.88 | 2022-2024 | Wallach Cryosurgical Equipment, Summit Doppler |
| Cardiovascular Systems INC. | $176.00 | 2022 | |
| Meditrina | $140.04 | 2024 | |
| Ethicon US, LLC | $58.23 | 2019 | |
| Hologic Sales and Service, LLC | $42.18 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Astellas Pharma US INC | $31.78 | 2024 | Veozah |
| Therapeuticsmd, INC. | $23.02 | 2020 | |
| Abbvie INC. | $20.05 | 2019 | |
| Avion Pharmaceuticals | $19.79 | 2020 | |
| Roche Diagnostics Corporation | $17.82 | 2019 | |
| Sumitomo Pharma America, INC. | $15.22 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $14.98 | 2025 | Zurzuvae |
| Allergan, INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Alembik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.